We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.35% | 28.60 | 28.20 | 29.00 | 28.75 | 28.60 | 28.75 | 1,773,661 | 13:07:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -260.00 | 193.07M |
TIDMHVO
RNS Number : 2900B
hVIVO plc
09 January 2018
For immediate release 7.00am: 9 January 2018
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that application has been made to AIM for the admission of 23,675 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively per quarter. On 7 June 2017 Jaime Ellertson volunteered to reduce his Director's fee by 10% to $180k pa, then on 13 November 2017 his role changed from Non-Executive Chairman to Non-Executive Director and his Director's fee reduced to GBP50k pa. His quarterly purchase of shares has reduced accordingly as 40% of his Director's fee.
The New Ordinary Shares represent their investments for the quarter ended 31 December 2017. On 8 January 2018, Mr Ellertson invested in an additional 16,401 ordinary shares and Mr Winschel invested in an additional 7,274 ordinary shares, at a price of 55.0 pence per share.
Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,197,542 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 11 January 2018. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 128,814 and 57,397 ordinary shares of 5.0p in the Company respectively, representing 0.2% and less than 0.1% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the persons discharging managerial responsibilities/persons closely associated --- ----------------------------------------------------------- a) Name Jaime Ellertson and Jim Winschel --- ----------------- ---------------------------------------- 2 Reason for the notification --- ----------------------------------------------------------- a) Position/ Non-Executive Director status --- ----------------- ---------------------------------------- b) Initial Initial Notification notification/ Amendment --- ----------------- ---------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ----------------------------------------------------------- a) Name hVIVO plc --- ----------------- ---------------------------------------- b) Legal Entity N/A Identifier --- ----------------- ---------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ----------------------------------------------------------- a) Description Ordinary shares of 5 pence each of the financial instrument, GB00B6ZM0X53 type of instrument Identification code --- ----------------- ---------------------------------------- b) Nature Acquisition of ordinary shares of the transaction --- ----------------- ---------------------------------------- c) Currency GBP --- ----------------- ---------------------------------------- d) Price(s) Director Price (p) Volume and volume(s) ----------------- ---------- ------- Jaime Ellertson 55.0 16,401 ----------------- ---------- ------- Jim Winschel 55.0 7,274 ----------------- ---------- ------- --- ----------------- e) Aggregated information - Aggregated volume - Price 23,675 - Aggregated 55.0p total GBP13,021.25 --- ----------------- ---------------------------------------- f) Date of 8 January 2018 the transaction --- ----------------- ---------------------------------------- g) Place of London Stock Exchange, AIM the transaction --- ----------------- ----------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300 Kym Denny (Chief Executive Officer) Graham Yeatman (Chief Financial & Business Officer) Media Enquiries +1 919 710 9658 Susan Flood (Head of Marketing) Numis Securities Limited +44 207 260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Michael Burke (Corporate Broking) FTI Consulting Simon Conway / Victoria Foster Mitchell (UK) +44 203 727 1000 John Capodanno / Evan Smith (US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGUQAGUPRPPR
(END) Dow Jones Newswires
January 09, 2018 02:00 ET (07:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions